根据SELECT试验,在美国人群中,心血管事件的减少符合SEMAGLUTIDE的条件
Jay B Lusk1, LáShauntá Glover2, Samir Soneji3
1Department of Population Health Sciences, Duke University School of Medicine, Durham, NC; Department of Neurology, Duke University School of Medicine, Durham, NC.
American heart journal
|August 25, 2024
概括
广泛使用2.4毫克的塞马格卢提德可以预防许多心血管事件和死亡. 这项研究估计,随着血红的摄入量增加,主要心血管事件 (MACE) 和死亡率的显著减少.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 心血管疾病 (CVD) 仍然是全球主要的死亡原因.
- 二次预防策略对于减少经常性心血管事件至关重要.
- 塞马格卢提德2.4毫克是一种潜在的治疗选择,用于心血管疾病的二次预防.
研究的目的:
- 估计可预防的重大心血管事件 (MACE) 和因任何原因而导致的死亡人数,如果在全国范围内每周服用2.4毫克西马格卢提德,则可避免.
- 评估塞马格卢提德在二次心血管疾病预防中的潜在公共卫生影响.
主要方法:
- 使用了一个全国代表性的横截面研究 (NHANES 2017-2020).
- 估计在四年内预防了潜在的MACE和死亡事件.
- 专注于满足SELECT试验纳入标准的美国成年人.
主要成果:
- 大约有450万美国成年人有资格每周服用西马格卢二甲基2.4毫克.
- 在50%的吸收率下,塞马格卢提德可以在4年内预防35,633例MACE和22,117例全因死亡.
- 如果没有西马格卢提德,预计符合条件的人群中估计有356,329例MACE和232,808例死亡.
结论:
- 每周服用2.4毫克的西马格卢提德有很大的潜力降低心血管疾病和死亡率.
- 这种治疗方法的广泛获取和利用可能会对公共卫生结果产生重大影响.
- 符合条件的成年人口规模凸显了这一干预措施的重要性.
更多相关视频
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.1K
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167